
    
      Prospective phase II study aiming to improve the outcome in hypoxic resistent patients
      identified by FAZA-PET.

      Inclusion:

      Patients must fulfill the following:

      Positive hypoxic FAZA-PET Scanning (as described in DAHANCA 24 - see citation) Stage III-IV,
      Squamous cell carcinoma of the larynx, pharynx or oral cavity (HPVneg (oropharynx) Indication
      for hyperfractionated accelerated radiotherapy with concommitant cis-platin and nimorazole
    
  